Microba Life Sciences Limited (MAP.AX)
| Previous close | 0.1600 |
| Open | 0.1800 |
| Bid | 0.1800 x N/A |
| Ask | 0.1900 x N/A |
| Day's range | 0.1800 - 0.1900 |
| 52-week range | 0.1500 - 0.4247 |
| Volume | |
| Avg. volume | 184,824 |
| Market cap | 80.613M |
| Beta (5Y monthly) | 2.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on Track to Report Results in September and in Q4, 2023 BERKELEY, Calif. and MAINZ, Germany, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the results of the first six months and second quarter ending June 30, 2023 and provi
- Business Wire
First Distribution Agreement Executed with Sonic Healthcare
BRISBANE, Australia, July 05, 2023--Microba Life Sciences Limited (ASX: MAP) ("Microba") is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly owned subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba’s advanced infectious disease test MetaPanel™ in Australia (Distribution Agreement).
- Business Wire
Microba Commences Phase I Clinical Trial for IBD Therapeutic
BRISBANE, Australia, June 28, 2023--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") today announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease (IBD). This milestone brings Microba’s drug candidate MAP 315 into clinical development as a potential new treatment option for the millions of people suffering from ulcerative colitis.
